Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: VENATORX PHARMACEUTICALS INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-07-01 to 2023-09-15
Current total value of award: $10669276
Description: TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.